Vaccines
Vaccines are one of the most significant public health achievements of the last century. Their value extends beyond narrow health effects for vaccinated people to generating social and economic benefits.
Prevention pays off – so why aren’t we doing more of it?
5 June 2025
We know that immunisation pays off: the wider societal benefits of childhood immunisation programmes in low and middle income countries outweigh their costs up to 51 times while…
OHE submission to the UK Parliamentary Inquiry on an Ageing Society
20 May 2025
OHE’s written submission to parliament focused on raising population health in older age and increasing access to fertility treatments as two possible avenues to address the challenges of demographic change.
Analysing Global Immunisation Expenditure
15 April 2025
Immunisation programmes are foundational to public health. Organised by health authorities, they systematically deliver vaccines to susceptible populations to prevent the spread of infectious diseases.
Employer Costs from Respiratory Infections
16 December 2024
Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs and health-focused policies could help boost productivity, reduce costs, and address health inequities.
Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report
18 April 2024
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.
Socio-Economic Value of Adult Immunisation Programmes
18 April 2024
Adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised.
Valuing Vaccines: The Economics of Vaccines & Immunisations
19 April 2023
On 26th April we will be joined by global experts to discuss the value of equity in access to vaccines worldwide, and hear from practitioners in the economic evaluation of vaccines in resource constrained environments.
The Value of Vaccines and Taskforces
25 January 2023
Drawing on global experience, our panel will deep-dive into the effectiveness & value of vaccines and the taskforce model.
Would Waiving COVID-19 Vaccines Patents Save Lives?
18 May 2021
This blog discusses the rationale behind a COVID-19 patent waiver decision and contributes to the current debate by producing a balanced view on the benefits and…